IHC using anti-EDB-FN (G4) mAb revealed distinct staining patterns of EDB-FN expression in the tumors across treatment groups: control tumors showed heterogeneous, moderate EDB-FN staining (Figure 2E) non-responding tumors displayed relatively weak staining throughout (Figure 2F) and the SD tumors exhibited strong staining, particularly intense in the tumor periphery compared to the core (Figure 2G). This evidence concerns the gene FN1 and neoplasm.